前立腺がんの世界市場-2023年～2030年

市場概要

世界の前立腺がん市場は、2022年に117億米ドルに達し、2030年には216億米ドルに達するなど、有利な成長が予測されています。前立腺がん市場は、2023年から2030年にかけて8.1%のCAGRを示すと予測されます。

前立腺がんは、皮膚がんに次いで男性に発生する代表的ながんの第2位です。前立腺がんの有病率の増加、早期診断に関する意識の向上、医療領域における洗練された手法の利用可能性が、市場成長の原動力となっています。

製品イントロダクションの増加も、予測期間中の世界の前立腺がん市場を牽引します。例えば、2022年3月、米国FDAは、前立腺特異的膜抗原陽性転移性去勢抵抗性前立腺がんという特定の種類の進行性がんに罹患している成人患者の治療薬として、スイス・米国の多国籍製薬企業であるノバルティスのPluvicto（lutetium Lu 177 vipivotide tetraxetan）を承認しました。

市場力学

前立腺がん患者の増加が予測期間中の前立腺がん世界市場を牽引

前立腺がんの罹患数の増加が、予測期間中の世界市場を牽引します。例えば、米国臨床腫瘍学会（ASCO）によると、前立腺がんは、皮膚がん以外に、男性で最も典型的ながんです。

2023年には、米国で推定288,300人の男性が前立腺がんと診断されます。一方、世界全体では、2020年に推定1,414,259人が前立腺がんと診断されました。前立腺がんは、世界で4番目に多く発見されるがんです。

活発化する取り組みが世界の前立腺がん市場に有望な成長機会をもたらす

前立腺がん患者を支援するイニシアチブの増加は、前立腺がんの世界市場に今後数年間の有利な成長機会をもたらしています。例えば、2022年4月、マウントサイナイのミルトン・アンド・キャロル・ペトリー泌尿器科は、黒人コミュニティの前立腺の健康を支援するために、マウントサイナイ・ロバート・F・スミス移動前立腺がん検診ユニットを設立しました。

COVID-19影響分析

COVID-19の分析には、COVID前シナリオ、COVIDシナリオ、COVID後シナリオに加え、価格力学（COVID前シナリオと比較したパンデミック中およびパンデミック後の価格変動を含む）、需給スペクトラム（取引制限、封鎖、およびその後の問題による需要と供給のシフト）、政府の取り組み（政府機関による市場、セクター、産業を復興させる取り組み）、メーカーの戦略的取り組み（COVID問題を緩和するためにメーカーが行ったことをここで取り上げる）が含まれます。

ロシア・ウクライナ戦争の影響分析

ウクライナでの戦乱により数百万人が混乱し、根こそぎにされたため、多数のウクライナ人が国家の西部地域に逃れなければならず、欧州や国外で難民となっています。その中には前立腺がん患者も含まれており、彼らは極度の病気と亡命という壮絶な一騎打ちに遭遇しました。

そして、ウクライナのがん病院が閑古鳥が鳴き、攻撃さえされる一方で、制裁とインフレに見舞われた国境を越えたウクライナの患者たちは、治療のための無期限の未来にさえ遭遇しています。

世界不況の影響分析

過去の金融不況時に医療機関が解雇や雇用を考えたように、ヘルスケア業界は不況と完全に無縁ではないです。とはいえ、この業界はその本質的な性質から、他のセクターよりはうまく対処しています。しかし、インフレが続く中、景気後退の危機は市場を脅かしています。

世界の先進諸国における高インフレは、過去2年間にわたる一般的なコスト高騰となって表れており、景気後退の持続に対する緊張の高まりが高まっています。一般的な購買力の累積的な悪化は、特に成長経済に影響を与えると予想され、多くの点で有用であると考えられています。

人工知能の影響分析

人工知能は、前立腺がんの診断と薬剤開発への応用の増加により、予測期間中、世界の前立腺がん市場にプラスの影響を与えます。例えば、aiモデルは、非侵襲的な放射線画像（超音波やMRI）、前立腺生検で得られた病理組織画像上でのがんの診断や攻撃性の等級付けを支援することができます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 製品認可の増加
    • 前立腺がんの有病率の増加
  • 抑制要因
    • 厳しい規制当局
  • 機会
  • 政府の取り組み
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• 規制分析
• 価格分析
• 特許分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 世界不況分析

第9章 人工知能影響分析

第10章 治療タイプ別

• ホルモン療法
• 化学療法
• 免疫療法
• 放射線療法
• 外部照射療法
• ブラキセラピー
• 局所療法
• 凍結手術
• 高密度焦点式超音波（HIFU）

第11章 エンドユーザー別

• 病院
• 外来手術センター
• 専門クリニック
• がんリハビリセンター

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 市場シェア分析
• M&A分析

第14章 企業プロファイル

• Johnson & Johnson
  • 企業概要
  • 治療タイプのポートフォリオと概要
  • 財務概要
  • 主な発展
• Astella, Inc.
• Sanofi Aventis
• IPSEN
• Bayer AG
• AstraZeneca
• Valent Pharmaceuticals LLC
• Sanofi-Aventis
• Pfizer Inc.
• Novartis International AG

第15章 付録

Market Overview

The Global Prostate Cancer Market reached US$ 11.7 billion in 2022 and is projected to witness lucrative growth by reaching US$ 21.6 billion by 2030. The Prostate Cancer Market is expected to exhibit a CAGR of 8.1% from 2023 to 2030.

Prostate cancer is the second-most typical cancer arising in males, behind skin cancer. The growing prevalence of prostate cancer, raising awareness concerning early diagnosis, and the availability of sophisticated methods present in the medical domain are driving market growth.

The increasing product introductions also drive the global prostate cancer market during the forecast period. For instance, in March 2022, the US FDA authorized Novartis, a Swiss-American multinational pharmaceutical corporation's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) indicated for the therapy of adult individuals suffering from a specific kind of progressive cancer named prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

Market Dynamics

The Growing Cases of Prostate Cancer are Driving the Global Prostate Cancer Market in the Forecast Period

The growing incidences of prostate cancer drive the global market during the forecast period. For instance, according to the American Society of Clinical Oncology (ASCO), prostate cancer, besides skin cancer, is the most typical cancer in males.

In 2023, an estimated 288,300 males in the United States will be detected with prostate cancer. While, globally, an estimated 1,414,259 individuals were seen with prostate cancer in 2020. Prostate cancer is the fourth most typically detected cancer in the world.

The Increasing Initiatives are Providing the Global Prostate Cancer Market with Prospective Growth Opportunities

The increasing initiatives to support prostate cancer patients present the Global Prostate Cancer Market with lucrative growth opportunities in the upcoming years. For instance, in April 2022, the Milton and Carroll Petrie Department of Urology at Mount Sinai established the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit to help prostate health in the Black community.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it to pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

As the warfare in Ukraine released disorder and uprooted millions of individuals, numerous Ukrainians had to escape to the western region of the nation and became refugees in Europe and outside. Among them were individuals with prostate cancer, who encountered a fierce one-two force of extreme sickness and exile.

And while cancer hospitals in Ukraine are being deserted or even attacked, Ukrainian patients across the boundary, struck by sanctions and inflation, even encounter an indefinite future for their care.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing.

The elevated extent of tension about the persistent recession as the high inflation in developed countries worldwide has transpired in a general cost surge over the past two years. The cumulatively deteriorating general purchasing control is anticipated to affect growing economies particularly and is considered helpful in numerous ways.

Artificial Intelligence Impact Analysis

Artificial intelligence positively impacts the Global Prostate Cancer Market during the forecast period, owing to its increased application in prostate cancer diagnosis and drug development. For instance, ai models can assist in diagnosing and grading cancer aggressiveness on non-invasive radiology pictures (Ultrasound and MRI), and on histopathology images obtained via prostate biopsy.

Segment Analysis

The Global Prostate Cancer Market is segmented based on therapy type, end-user, and region.

The Chemotherapy Segment is Estimated To Hold a 30.6% Share of the Global Market.

The chemotherapy segment is estimated to hold about 30.6% of the global prostate cancer market owing to the increasing research development in the part. For instance, in February 2023, investigators from Sanford Burnham Prebys, a non-profit medical research institute concentrating on fundamental and translational studies, found that prostate cancer can be killed by targeting a single enzyme called PI5P4Kα.

Geographical Analysis

Europe is Estimated to Hold the Second-Largest Share of the Global Prostate Cancer Market During the Forecast Period.

Owing to the growing number of prostate cancer cases and initiatives to battle against prostate cancer, Europe is estimated to hold about 26.8% of the global prostate cancer market. For instance, according to the European Federation of Pharmaceutical Industries and Associations, over 30 million males in Europe are detected with prostate cancer in their lifetime and every year more than 75,000 males die from prostate cancer in Europe.

Moreover, the introduction of the EU4Health program has supported PRAISE-U (PRostate cancer Awareness and Initiative for Screening in the European Union), an ambitious three-year task concerning 25 organizations from 12 nations. PRAISE-U's task is to develop a nationally-tailored cost-effective early diagnosis algorithm for prostate cancer filtering in the EU to decrease mortality and morbidity induced by prostate cancer while evading overdiagnosis and overtreatment.

Competitive Landscape

The major global players in the market include: Johnson & Johnson, Astella, Inc., Sanofi Aventis, IPSEN, Bayer AG, AstraZeneca, Valent Pharmaceuticals LLC, Novartis International AG, and Clovis Oncology Inc., among others.

Why Purchase the Report?

• To visualize the Global Prostate Cancer Market segmentation based on therapy type, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous prostate cancer market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Prostate Cancer Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Therapy Type
• 3.2. Snippet by End User
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Product Approvals
    • 4.1.1.2. Growing Prostate Cancer Prevalence
  • 4.1.2. Restraints
    • 4.1.2.1. Stringent Regulatory Authorities
  • 4.1.3. Opportunity
  • 4.1.4. Government Initiatives
  • 4.1.5. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Regulatory Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Post COVID-19 & Future Scenario
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Therapy Type

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 10.1.2. Market Attractiveness Index, By Therapy Type
• 10.2. Hormone therapy
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Chemotherapy
• 10.4. Immunotherapy
• 10.5. Radiation
• 10.6. External-beam radiation therapy
• 10.7. Brachytherapy
• 10.8. Focal therapies
• 10.9. Cryosurgery
• 10.10. High-intensity focused ultrasound (HIFU)

11. By End User

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.1.2. Market Attractiveness Index, By End User
• 11.2. Hospitals
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Ambulatory Surgical Centers
• 11.4. Specialty Clinics
• 11.5. Cancer Rehabilitation Centers

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.5.1. The U.S.
    • 12.2.5.2. Canada
    • 12.2.5.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.5.1. Germany
    • 12.3.5.2. The U.K.
    • 12.3.5.3. France
    • 12.3.5.4. Italy
    • 12.3.5.5. Spain
    • 12.3.5.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.5.1. Brazil
    • 12.4.5.2. Argentina
    • 12.4.5.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.5.1. China
    • 12.5.5.2. India
    • 12.5.5.3. Japan
    • 12.5.5.4. Australia
    • 12.5.5.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Market Share Analysis
• 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

• 14.1. Johnson & Johnson
  • 14.1.1. Company Overview
  • 14.1.2. Therapy Type Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. Astella, Inc.
• 14.3. Sanofi Aventis
• 14.4. IPSEN
• 14.5. Bayer AG
• 14.6. AstraZeneca
• 14.7. Valent Pharmaceuticals LLC
• 14.8. Sanofi-Aventis
• 14.9. Pfizer Inc.
• 14.10. Novartis International AG

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us